Friday, September 25, 2020 7:17:32 PM
Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam)
Recent AQST News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 09:10:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 09:05:43 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 09:00:52 PM
- AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: SueWallSt • PR Newswire (US) • 04/23/2026 01:00:00 PM
- AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/21/2026 01:00:00 PM
- AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/14/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:54:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:54:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:53:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:52:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:51:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 01:56:19 PM
- AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/07/2026 01:00:00 PM
- AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm • PR Newswire (US) • 03/31/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:44:46 AM
- Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt • PR Newswire (US) • 03/26/2026 01:00:00 PM
- AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm • PR Newswire (US) • 03/24/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 11:36:04 AM
- Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer • GlobeNewswire Inc. • 03/20/2026 11:00:00 AM
- AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm • PR Newswire (US) • 03/17/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 04:52:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 04:52:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 04:52:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 04:51:23 PM
